1-19 of 19
Alwin Schuller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5604: Targeting CD73 augments the efficacy of A2aR blockade in PTEN-deficient prostate cancer

Marco A. De Velasco, Yurie Kura, Naomi Ando, Noriko Sako, Kazuko Sakai, Alwin Schuller, Kris Sachsenmeier, Kazutoshi Fujita, Eri Banno, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuto Nishio, Hirotsugu Uemura
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5604.
https://doi.org/10.1158/1538-7445.AM2022-5604
Published: 15 June 2022
View article titled, Abstract 5604: Targeting CD73 augments the efficacy of A2aR blockade in PTEN-deficient prostate cancer
Journal Articles

Abstract 6103: Reshaping the myeloid-dependent pro-tumorigenic microenvironment in PDAC by targeting the extracellular adenosine pathway: A therapeutic opportunity

Vincenzo Graziano, Andreas Dannhorn, Kate Williamson, Heather Hulme, Hannah Buckley, Sheng Y. Lee, Sabita Islam, James E. Thaventhiran, Richard Goodwin, Rebecca Brais, Simon J. Dovedi, Alwin Schuller, Jim Eyles, Duncan I. Jodrell
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6103.
https://doi.org/10.1158/1538-7445.AM2022-6103
Published: 15 June 2022
View article titled, Abstract 6103: Reshaping the myeloid-dependent pro-tumorigenic microenvironment in PDAC by targeting the extracellular adenosine pathway: A therapeutic opportunity
Journal Articles

Abstract 1664: Inhibition of arginase in combination with radiation therapy shows increased immune-activation and anti-tumor activity in syngeneic tumor models

Alwin Schuller, Aatman Doshi, Susan Cantin, Matt Griffin, Maryann San Martin, Theresa Proia, Corinne Reimer, Scott Mlynarski, Ray Finlay, Wenlin Shao
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1664.
https://doi.org/10.1158/1538-7445.AM2021-1664
Published: 01 July 2021
View article titled, Abstract 1664: Inhibition of arginase in combination with radiation therapy shows increased immune-activation and anti-tumor activity in syngeneic tumor models
Journal Articles

Abstract 1695: Activation of B cells by CD73 blocking antibodies

James Hair, Fabien Garcon, Michelle Hsueh, Laura Dallaway, Elena Bibikova, Maria Letizia Giardino Torchia, Gordon Moody, Alwin Schuller, Simon J. Dovedi, Zachary A. Cooper, Kris Sachsenmeier, Rakesh Kumar, Jim Eyles, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1695.
https://doi.org/10.1158/1538-7445.AM2021-1695
Published: 01 July 2021
View article titled, Abstract 1695: Activation of B cells by CD73 blocking antibodies
Journal Articles

Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer

Marco A. De Velasco, Yurie Kura, Noriko Sako, Naomi Ando, Kazuko Sakai, Alwin Schuller, Kazutoshi Fujita, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuto Nishio, Hirotsugu Uemura
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1568.
https://doi.org/10.1158/1538-7445.AM2021-1568
Published: 01 July 2021
View article titled, Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer
Journal Articles

Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models

Jim Eyles, Amanda Watkins, Kristina Ilieva, Stef Mullins, Jude Anderton, Elena Galvani, Fabien Garcon, Kelli Ryan, Brajesh P. Kaistha, Andreas Dannhorn, Stephanie Ling, Tim Slidel, Gozde Kar, Alwin Schuller, Zachary A. Cooper, Kris Sachsenmeier, Nadia Luheshi, Rakesh Kumar, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1584.
https://doi.org/10.1158/1538-7445.AM2021-1584
Published: 01 July 2021
View article titled, Abstract 1584: Efficacy and pharmacodynamic effect of anti-CD73/PD-L1 monoclonal antibodies in combination with chemotherapy: Observations from mouse tumor models
Journal Articles

Abstract 1071: Targeting A2aR in mouse Pten-deficient prostate cancer

Marco A. De Velasco, Yurie Kura, Noriko Sako, Naomi Ando, Kazuko Sakai, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Alwin Schuller, Kazuto Nishio, Hirotsugu Uemura
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1071.
https://doi.org/10.1158/1538-7445.AM2020-1071
Published: 15 August 2020
View article titled, Abstract 1071: Targeting A2aR in mouse <em>Pten</em>-deficient prostate cancer
Journal Articles

Abstract 4523: Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in mouse syngeneic tumor models

Alwin Schuller, Aatman Doshi, Susan Cantin, Michael Secinaro, Yanjun Wang, Laura Prickett, Sharon Tentarelli, Eric Gangl, Horma Ghadially, Kristina Ilieva, Theresa Proia, Scott Mlynarski, Ray Finlay, Wenlin Shao
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4523.
https://doi.org/10.1158/1538-7445.AM2020-4523
Published: 15 August 2020
View article titled, Abstract 4523: Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in mouse syngeneic tumor models
Journal Articles

Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells

Christine M. Barbon, Alexandra Borodovsky, Yanjun Wang, Laura Prickett, Kris Sachsenmeier, Alwin Schuller, Wenlin Shao, Carl Barrett, Stephen Fawell, Deanna A. Mele
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-192.
https://doi.org/10.1158/1538-7445.AM2019-LB-192
Published: 01 July 2019
View article titled, Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells
Journal Articles

Abstract 299: A susceptible-quiescent model can describe biphasic cell-kill by MCL1 inhibitor AZD5991 in vitro

Francis D. Gibbons, Matthew Belmonte, Paul Secrist, Alwin Schuller
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 299.
https://doi.org/10.1158/1538-7445.AM2018-299
Published: 01 July 2018
View article titled, Abstract 299: A susceptible-quiescent model can describe biphasic cell-kill by MCL1 inhibitor AZD5991 <em>in vitro</em>
Journal Articles

Abstract 302: Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves antitumor activity in multiple myeloma and acute myeloid leukemia

Adriana E. Tron, Matthew A. Belmonte, Steven Criscione, Edwin A. Clark, Eric Gangl, Francis D. Gibbons, Jeffrey W. Tyner, Stephen E. Kurtz, Qing Ye, Alexander W. Hird, Alwin Schuller, J. Paul Secrist
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 302.
https://doi.org/10.1158/1538-7445.AM2018-302
Published: 01 July 2018
View article titled, Abstract 302: Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves antitumor activity in multiple myeloma and acute myeloid leukemia
Journal Articles

Abstract 4263: A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model

Rhys D. Jones, Michael Grondine, Alexandra Borodovsky, Maryann San Martin, Michelle DuPont, Celina D'Cruz, Alwin Schuller, Ryan Henry, Evan Barry, Klas Petersson, Tarjinder Sahota, Ghada F. Ahmed
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4263.
https://doi.org/10.1158/1538-7445.AM2018-4263
Published: 01 July 2018
View article titled, Abstract 4263: A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model
Journal Articles

Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models

Alwin Schuller, Evan Barry, Rhys Jones, Melanie Frigault, Garry Beran, Ryan Henry, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen Fawell, Edwin Clark, Celina D'Cruz
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1477.
https://doi.org/10.1158/1538-7445.AM2015-1477
Published: 01 August 2015
View article titled, Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models
Journal Articles

Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291

Celina D'Cruz, Evan Barry, Ryan Henry, Lillian Castriotta, Alwin Schuller, Garry Beran, Susan Ashton, Cath Eberlein, Corinne Reimer, Melanie Frigault, Michael Zinda, Darren Cross, Stephen Fawell
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 761.
https://doi.org/10.1158/1538-7445.AM2015-761
Published: 01 August 2015
View article titled, Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291
Journal Articles

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Andrew P. Garner, Carl U. Bialucha, Elizabeth R. Sprague, Joan T. Garrett, Qing Sheng, Sharon Li, Olga Sineshchekova, Parmita Saxena, Cammie R. Sutton, Dongshu Chen, Yan Chen, Huiqin Wang, Jinsheng Liang, Rita Das, Rebecca Mosher, Jian Gu, Alan Huang, Nicole Haubst, Carolin Zehetmeier, Manuela Haberl, Winfried Elis, Christian Kunz, Analeah B. Heidt, Kara Herlihy, Joshua Murtie, Alwin Schuller, Carlos L. Arteaga, William R. Sellers, Seth A. Ettenberg
Journal: Cancer Research
Cancer Res (2013) 73 (19): 6024–6035.
https://doi.org/10.1158/0008-5472.CAN-13-1198
Published: 01 October 2013
View article titled, An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Open the PDF for An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin in another window
Includes: Supplementary data
Journal Articles

Abstract 699: Optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models.

Alwin Schuller, Robert Booher, Louise Cadzow, Minilik Angagaw, Lauren Harmonay, Xianlu Qu, Nathan Miselis, Vincenzo Pucci, Mark Ayers, Thorsten Graef, Ellie Im, Rebecca Blanchard, Brian Long, Leigh Zawel, peter strack
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 699.
https://doi.org/10.1158/1538-7445.AM2013-699
Published: 15 April 2013
View article titled, Abstract 699: Optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models.
Journal Articles

Abstract 698: MCL1 dependent cells are sensitive to the CDK inhibitor Dinaciclib.

Harold Hatch, Robert Booher, Samanthi Perera, Thi Nguyen, Brian Dolinski, Samer Al-Assaad, Lauren Harmonay, Alwin Schuller, Minilik Angagaw, Brian Long, Xianlu Qu, Nathan Miselis, Mark Ayers, Michael Nebozhyn, Heather Hirsch, Danielle Greenawalt, Andrey Loboda, Thorseten Graef, Ellie Im, Rebecca Blanchard, Leigh Zawel, Peter Strack
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 698.
https://doi.org/10.1158/1538-7445.AM2013-698
Published: 15 April 2013
View article titled, Abstract 698: MCL1 dependent cells are sensitive to the CDK inhibitor Dinaciclib.
Journal Articles

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

Heather Huet, Alwin Schuller, Jing Li, Jennifer Johnson, Bruno Dombrecht, Kris Meerschaert, Karen Cromie, Sanela Bilic, Sharon Li, Andrew Garner, Sandra Nunes, Rajiv Chopra, Kirk Clark, Megan Yao, Stephen Fawell, David Stover, William R. Sellers, Seth Ettenberg
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3853.
https://doi.org/10.1158/1538-7445.AM2012-3853
Published: 15 April 2012
View article titled, Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches
Journal Articles

Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation.

Andrew Garner, Qing Sheng, Uli Bialucha, Dongshu Chen, Yan Chen, Rita Das, Winfried Elis, Analeah Heidt, Christian Kunz, Sharon Li, Jinsheng Liang, Joshua Murtie, Parmita Saxena, Alwin Schuller, Olga Sineshchekova, Elizabeth Sprague, Hui Qin Wang, Alan Huang, Seth Ettenberg
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2733.
https://doi.org/10.1158/1538-7445.AM2012-2733
Published: 15 April 2012
View article titled, Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation.